Cannabis Testing

Tucson-based PathogenDx, a provider of DNA-based pathogen screening packages for the marijuana, botanical, food and farming industries, has received a minority equity financial investment from Salveo Capital, an alternative financial investment firm focusing on the legalized marijuana market.

PathogenDx’s technology offers growers, processors, producers, customers and ancillary provider with real-time information and information referring to the quality of their product. The technology provides consumers with access to accurate real-time responses to figure out if their plants or crops have been polluted with fungis, molds, viruses or mildew.

” With its cutting edge services and high quality products, PathogenDx represents an ingenious and disruptive business that is changing the screening procedure for cannabis-related items as we know it,” stated Jeffrey Howard, a Managing Partner at Salveo Capital. “We believe that as consumers and growers continue to seek the latest and biggest approaches to ensure the utmost quality and pureness in their product, the need for PathogenDx’s services will continue to rise. We are enjoyed finish this investment and are very much anticipating partnering with the whole PathogenDx group to drive further worth into the business.”

Milan Patel, CEO and Co-Founder of PathogenDx, said, “As we participate in the next phase as a company, it is critical that we have the strategic support in place to offer our customers with the premier product or services they have concerned anticipate in the most simplistic and affordable manner. We are confident that Salveo’s financial investment and operational experience within the cannabis space will promote substantial growth, assist us expand into brand-new markets, and continue to guarantee the safest possible items from a human health viewpoint. We are honored to welcome Salveo as an investor and are eager to start working together with their team.”

AP Photo/Jeff Chiu

Share story: